Nifty Pharma Index Falls 0.5 Percent on 7 July 2026 as Biocon, Laurus Labs and Wockhardt Lead Losses
- July 7, 2026
- Posted by: Ankit Jaiswal
- Category: News
Nifty Pharma index down 0.73% at 25,677.70 on 7 July 2026. Biocon -3.17%, Laurus Labs -3.05%, Wockhardt -2.8% lead losses among 10 pharma stocks.
The Nifty Pharma index fell on 7 July 2026, trading at 25,677.70, down 0.73 percent, with Biocon leading the decline, down 3.17 percent, followed by Laurus Labs, down 3.05 percent, and Wockhardt, down 2.8 percent.
The broad-based weakness across the pharma sector came even as IT stocks rallied sharply elsewhere in the market, underlining that today’s pharma decline reflects sector-specific profit booking rather than a market-wide risk-off move.
Click Here – Get Free Investment Predictions
Nifty Pharma Index Top Losers Today
| Company | CMP (Rs) | Change (%) | Volume |
|---|---|---|---|
| Biocon | 410.85 | -3.17 | 2.28m |
| Laurus Labs | 1,482.60 | -3.05 | 1.75m |
| Wockhardt | 1,861.80 | -2.80 | 435.34k |
| Ajanta Pharma | 3,311.90 | -1.83 | 50.71k |
| Piramal Pharma | 175.11 | -1.56 | 4.32m |
| Divis Labs | 6,772.50 | -1.24 | 344.98k |
| Cipla | 1,457.60 | -1.00 | 813.21k |
| Abbott India | 26,645.00 | -0.80 | 4.68k |
| Mankind Pharma | 2,523.90 | -0.69 | 173.77k |
| Aurobindo Pharm | 1,586.70 | -0.50 | 477.33k |
Why the Nifty Pharma Index Is Under Pressure Today
Biocon’s 3.17 percent decline leads the sector lower, with biosimilar and generic-focused names like Laurus Labs and Wockhardt also posting sharp falls of around 3 percent each. This breadth of weakness across biosimilars, contract research and generics suggests broad profit booking after a period of relative outperformance in the pharma sector, rather than a company-specific trigger isolated to any single name.
Mankind Pharma’s more modest 0.69 percent decline comes on the same day InCred initiated an add rating on the stock with a Rs 2,812 target, suggesting the stock-specific brokerage note has provided some cushion relative to sharper-falling peers within the Nifty Pharma index.
Get Research-Backed Stock Ideas from a SEBI Registered Investment Advisor
Which Pharma Stocks Held Up Better
Mankind Pharma and Aurobindo Pharma were the relative outperformers within the Nifty Pharma index today, both down less than 0.7 percent, compared to declines of over 3 percent in Biocon and Laurus Labs. Abbott India, a more defensive branded formulations player, also declined a more modest 0.8 percent, showing that domestic-facing pharma names held up somewhat better than export and biosimilar-focused peers today.
What Should Investors Watch for the Nifty Pharma Index
Investors tracking the Nifty Pharma index should watch upcoming Q1 FY27 results from major constituents for commentary on US generic pricing trends, biosimilar approval pipelines, and domestic formulation growth, along with any fresh regulatory developments from the US FDA that could affect specific companies within the index.
Download the Univest iOS App or Univest Android App to track the Nifty Pharma index and all pharma stocks live.
Conclusion
The Nifty Pharma index fell 0.73 percent to 25,677.70 on 7 July 2026, led by declines in Biocon, Laurus Labs and Wockhardt, while Mankind Pharma and Aurobindo Pharma held up relatively better. The broad-based nature of the decline points to sector-wide profit booking rather than a single company-specific issue. Q1 FY27 earnings commentary is the next thing to watch.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on the Nifty Pharma Index
Why is the Nifty Pharma index falling today?
Ans. The Nifty Pharma index fell 0.73 percent on 7 July 2026 due to broad-based profit booking across the sector, with Biocon, Laurus Labs and Wockhardt among the top losers.
Which stock led the fall in the Nifty Pharma index?
Ans. Biocon led the decline, falling 3.17 percent, followed by Laurus Labs down 3.05 percent and Wockhardt down 2.8 percent.
Which pharma stocks held up better today?
Ans. Mankind Pharma and Aurobindo Pharma were the relative outperformers within the Nifty Pharma index, both down less than 0.7 percent, compared to sharper declines of over 3 percent in Biocon and Laurus Labs.
What is the Nifty Pharma index level today?
Ans. The Nifty Pharma index was trading at 25,677.70 on 7 July 2026, down 0.73 percent from the previous close of 25,866.25.
Why did Mankind Pharma hold up better than other pharma stocks today?
Ans. Mankind Pharma’s more modest 0.69 percent decline comes on the same day InCred initiated an add rating on the stock with a Rs 2,812 target, which may have provided some cushion relative to sharper-falling peers.
Is the Nifty Pharma decline linked to the broader market today?
Ans. No, the decline appears sector-specific, as IT stocks rallied sharply in the same session, indicating today’s pharma weakness reflects sector rotation rather than a broad market risk-off move.
Should investors buy pharma stocks after today’s fall?
Ans. This article does not constitute investment advice. Investors should evaluate individual company fundamentals, US generic pricing trends and valuations, and consult a SEBI registered financial advisor before investing.
